The deal will focus on the manufacturing of a genome edited cell therapy for Friedreich’s ataxia.
Cellares and Papillon Therapeutics partner to scale orphan drug production
The deal will focus on the manufacturing of a genome edited cell therapy for Friedreich’s ataxia.